Bernhard R. M. Ehmer
Chairman chez BIOTEST AG
Fortune : 94 515 $ au 31/03/2024
Profil
Bernhard R.
M.
Ehmer currently works at Biotest AG, as Chairman-Supervisory Board from 2022, Achilles Therapeutics Plc, as Independent Non-Executive Director from 2022, Affimed NV, as Independent Member-Supervisory Board from 2016, and Affimed GmbH, as Member-Supervisory Board from 2016.
Dr. Ehmer also formerly worked at Biopheresis GmbH, as Chief Executive Officer & Managing Director from 2006 to 2007, BioPheresis Technologies, Inc., as Chief Executive Officer & Managing Director from 2006 to 2007, Neovii Biotech GmbH, as President & Chief Executive Officer from 2007 to 2008, Biotest AG, as Chairman-Management Board from 2015 to 2019, Symphogen A, as Chairman from 2018 to 2020, ADMA Biologics, Inc., as Director from 2017 to 2018, Hybrigenics SA, as Director, ImClone Systems International GmbH, as Managing Director & Senior Vice President from 2008 to 2012, Merck KGaA, as VP, Head-Strategic Planning & Alliance Management from 1988 to 2006, Merck KGaA, as Head-Clinical Research & Development Operations from 1998 to 2006, Boehringer Mannheim GmbH, as Head-Therapeutics & Medical Operations from 1986 to 1998, and ImClone Systems Corp., as President from 2009 to 2014.
Dr. Ehmer received his undergraduate degree in 1982 from Ruprecht-Karls-Universität Heidelberg and undergraduate degree in 1982 from Ludwig-Maximilians-Universität München.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
AFFIMED N.V.
0,12% | 15/03/2023 | 17 833 ( 0,12% ) | 94 515 $ | 31/03/2024 |
Postes actifs de Bernhard R. M. Ehmer
Sociétés | Poste | Début |
---|---|---|
AFFIMED N.V. | Director/Board Member | 21/01/2016 |
ACHILLES THERAPEUTICS PLC | Director/Board Member | 04/05/2022 |
BIOTEST AG | Chairman | 05/05/2022 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Board Member | 01/01/2016 |
Anciens postes connus de Bernhard R. M. Ehmer
Sociétés | Poste | Fin |
---|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Chairman | 01/06/2020 |
BIOTEST AG | Chief Executive Officer | 01/04/2019 |
ADMA BIOLOGICS, INC. | Director/Board Member | 15/02/2018 |
ImClone Systems Corp. | President | 01/10/2014 |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/2012 |
Formation de Bernhard R. M. Ehmer
Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 6 |
---|---|
MERCK KGAA | Health Technology |
ADMA BIOLOGICS, INC. | Health Technology |
AFFIMED N.V. | Health Technology |
BIOTEST AG | Health Technology |
ATON | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Entreprise privées | 8 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Biopheresis GmbH
Biopheresis GmbH Miscellaneous Commercial ServicesCommercial Services Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The private company is based in Heidelberg, Germany. | Commercial Services |
BioPheresis Technologies, Inc.
BioPheresis Technologies, Inc. Medical SpecialtiesHealth Technology BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA. | Health Technology |
Boehringer Mannheim GmbH | |
ImClone Systems International GmbH
ImClone Systems International GmbH BiotechnologyHealth Technology ImClone Systems International GmbH develops novel therapeutic products. The company is based in Heidelberg, Germany. | Health Technology |
ImClone Systems Corp. | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |